Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter

American Journal of Emergency Medicine

Volumn 24, Issue 4, 2006, Pages 407-412

  Mountantonakis, Stavros E ^a,b,c   Moutzouris, Dimitrios A ^a   Tiu, Ramon V ^c   Papaioannou, Georgios N ^a   McPherson, Craig A ^b  

^a Livadias General Hospital   (Greece)

^b BRIDGEPORT HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUTILIDE;

AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; EMERGENCY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SAMPLE SIZE; SINUS RHYTHM; SYMPTOM; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TORSADE DES POINTES; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALS, COMMUNITY; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; METOPROLOL; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 33745258215     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2005.12.006     Document Type: Article

References (35)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001) 2370
2. [No authors listed]. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 4: devices to assist circulation. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 102 8 Suppl (2000) I105-I111
3. Mulcahy B., Coates W.C., Henneman Pl., et al. New-onset atrial fibrillation: when is admission medically justified?. Acad Emerg Med 3 2 (1996) 114-119
4. Weigner M.J., Caulfield T.A., Danias P.G., et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 126 8 (1997) 615-620
5. Falk R.H. Atrial fibrillation. N Engl J Med 344 14 (2001) 1067-1078
6. Michael J.A., Stiell I.G., Agarwal S., et al. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 33 4 (1999) 379-387
7. Botto G.L., Bonini W., Broffoni T., et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?. Pacing Clin Electrophysiol 19 11 Pt 2 (1996) 1939-1943
8. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 262 1 (1992) 99-108
9. Ellenbogen K.A., Clemo H.F., Stambler B.S., et al. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 78 8A (1996) 42-45
10. Murray K.T. Ibutilide. Circulation 97 (1998) 493-497
11. Ellenbogen K.A., Stambler B.S., Wood M.A., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 1 (1996) 130-136
12. Eversole A., Hancock W., Johns T., et al. Ibutilide: efficacy and safety in atrial fibrillation and atrial flutter in a general cardiology practice. Clin Cardiol 24 7 (2001) 521-525
13. Stambler B.S., Wood M.A., Ellenbogen K.A., et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94 7 (1996) 1613-1621
14. Abi-Mansour P., Carberry P.A., McCowan R.J., et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am J Heart 136 4 Pt 1 (1998) 632-642
15. Vos M.A., Golitsyn S.R., Stangl K., et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 79 6 (1998) 568-575
16. Volgman A.S., Carberry P.A., Stambler B., et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 31 6 (1998) 1414-1419
17. McNamara R.L., Tamariz L.J., Segal J.B., et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 139 12 (2003) 1018-1033
18. Howard P.A. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 33 1 (1999) 38-47
19. Kowey P.R., VanderLugt J.T., and Luderer J.R. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 78 8A (1996) 46-52
20. Rogers K.C., and Wolfe D.A. Ibutilide: a class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter. J Emerg Med 20 1 (2001) 67-71
21. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 23 (2002) 1825-1833
22. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and hm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 23 (2002) 1834-1840
23. Clementy J., Dulhoste M.N., Laiter C., et al. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 70 5 (1992) 44A-49A
24. Levy S., Maarek M., Coumel P., et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99 23 (1999) 3028-3035
25. Kopecky S.L., Gersh B.J., McGoon M.D., et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 317 11 (1987) 669-674
26. Pritchett E.L. Management of atrial fibrillation. N Engl J Med 326 19 (1992) 1264-1271
27. Antonielli E., Pizzuti A., Palinkas A., et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 39 9 (2002) 1443-1449
28. Oral H., Souza J.J., Michaud G.F., et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 340 24 (1999) 1849-1854
29. Cameron A., Schwartz M.J., Kronmal R.A., et al. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 61 10 (1988) 714-717
30. Zimetbaum P.J., Josephson M.E., McDonald M.J., et al. Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 36 4 (2000) 1223-1227
31. Israel C.W., Gronefeld G., Ehrlich J.R., et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 43 1 (2004) 47-52
32. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 38 (2001) 1231
33. Dell'Orfano J.T., and Naccarelli G.V. Update on external cardioversion and defibrillation. Curr Opin Cardiol 16 1 (2001) 54-57
34. Domanovits H., Schillinger M., Thoennissen J., et al. Termination of recent-onset atrial fibrillation/flutter in the emergency department: a sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation 45 3 (2000) 181-187
35. Kim MH, Conlon B, Ebinger M, et al. Clinical outcomes and costs associated with a first episode of uncomplicated atrial fibrillation presenting to the emergency room. Am J Cardiol 2001;88(1):A7, 74-76.